PT3805233T - Enantiómeros (r) e (s) de n-(5-(3-hidroxipirrolidin-1-il)-2 morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)oxazole-carboxamida como inibidores de irak4 para o tratamento de cancro - Google Patents

Enantiómeros (r) e (s) de n-(5-(3-hidroxipirrolidin-1-il)-2 morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)oxazole-carboxamida como inibidores de irak4 para o tratamento de cancro

Info

Publication number: PT3805233T
Authority: PT; Portugal
Prior art keywords: morpholinooxazolo; hydroxypyrrolidin; methylpyridin; oxazole; enantiomer
Prior art date: 2014-01-13

Application number

PT202110961T

Other languages

English (en)

Original Assignee

Aurigene Oncology Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-13

Filing date

2015-01-12

Publication date

2024-04-15

2015-01-12 Application filed by Aurigene Oncology Ltd filed Critical Aurigene Oncology Ltd

2024-04-15 Publication of PT3805233T publication Critical patent/PT3805233T/pt

Links

229940127590 IRAK4 inhibitor Drugs 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
208000027866 inflammatory disease Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)

PT202110961T 2014-01-13 2015-01-12 Enantiómeros (r) e (s) de n-(5-(3-hidroxipirrolidin-1-il)-2 morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)oxazole-carboxamida como inibidores de irak4 para o tratamento de cancro PT3805233T (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN158CH2014		2014-01-13
IN3000CH2014		2014-06-20

Publications (1)

Publication Number	Publication Date
PT3805233T true PT3805233T (pt)	2024-04-15

Family

ID=53523587

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PT202110961T PT3805233T (pt)	2014-01-13	2015-01-12	Enantiómeros (r) e (s) de n-(5-(3-hidroxipirrolidin-1-il)-2 morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)oxazole-carboxamida como inibidores de irak4 para o tratamento de cancro
PT181903337T PT3466955T (pt)	2014-01-13	2015-01-12	Método de preparação de derivados de oxazolo[4,5-b] piridina e tiazolo[4,5-b] piridina como inibidores de irak-4 para o tratamento do cancro
PT15735499T PT3094329T (pt)	2014-01-13	2015-01-12	Derivados de heterociclilo biciclico como inibidores de irak-4

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PT181903337T PT3466955T (pt)	2014-01-13	2015-01-12	Método de preparação de derivados de oxazolo[4,5-b] piridina e tiazolo[4,5-b] piridina como inibidores de irak-4 para o tratamento do cancro
PT15735499T PT3094329T (pt)	2014-01-13	2015-01-12	Derivados de heterociclilo biciclico como inibidores de irak-4

Country Status (31)

Country	Link
US (6)	US9732095B2 (pt)
EP (4)	EP3466955B1 (pt)
JP (5)	JP6479850B2 (pt)
KR (3)	KR102392684B1 (pt)
CN (2)	CN106456619B (pt)
AU (5)	AU2015205374B2 (pt)
BR (1)	BR112016016158B1 (pt)
CA (1)	CA2935887A1 (pt)
CU (1)	CU24389B1 (pt)
CY (2)	CY1121433T1 (pt)
DK (3)	DK3466955T3 (pt)
EA (2)	EA038748B1 (pt)
ES (2)	ES2846678T3 (pt)
FI (1)	FI3805233T3 (pt)
HK (1)	HK1231410A1 (pt)
HR (2)	HRP20181795T1 (pt)
HU (2)	HUE041926T2 (pt)
IL (6)	IL302878B1 (pt)
LT (3)	LT3805233T (pt)
MX (1)	MX359909B (pt)
MY (1)	MY197116A (pt)
NZ (2)	NZ760657A (pt)
PH (2)	PH12016501344A1 (pt)
PL (2)	PL3094329T3 (pt)
PT (3)	PT3805233T (pt)
RS (2)	RS61448B1 (pt)
SG (2)	SG10201811204RA (pt)
SI (2)	SI3094329T1 (pt)
TR (1)	TR201815683T4 (pt)
WO (1)	WO2015104688A1 (pt)
ZA (2)	ZA202007274B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201311888D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compounds
GB201311891D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compound
EA201691401A1 (ru)	2014-01-10	2016-11-30	Ориджин Дискавери Текнолоджиз Лимитед	Индазольные соединения в качестве ингибиторов irak4
LT3805233T (lt)	2014-01-13	2024-05-10	Aurigene Oncology Limited	N-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2- metilpiridin-4-il)oksazol-karboksamido (r) ir (s) enantiomerai, kaip irak4 inhibitoriai, skirti vėžio gydymui
WO2017009806A1 (en) *	2015-07-15	2017-01-19	Aurigene Discovery Technologies Limited	Substituted aza compounds as irak-4 inhibitors
CA2993661A1 (en)	2015-08-04	2017-02-09	Rigel Pharmaceuticals, Inc.	Benzazole compounds and methods for making and using the compounds
US10435396B2 (en)	2016-03-03	2019-10-08	Bayer Pharma Aktiegesellschaft	2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
JOP20180011A1 (ar)	2017-02-16	2019-01-30	Gilead Sciences Inc	مشتقات بيرولو [1، 2-b]بيريدازين
EP3600270B1 (en) *	2017-03-31	2023-06-14	Aurigene Oncology Limited	Compounds and compositions for treating hematological disorders
US11358948B2 (en)	2017-09-22	2022-06-14	Kymera Therapeutics, Inc.	CRBN ligands and uses thereof
CA3076613A1 (en)	2017-09-22	2019-03-28	Kymera Therapeutics, Inc.	Protein degraders and uses thereof
WO2019089580A1 (en) *	2017-10-31	2019-05-09	Curis, Inc.	Compounds and compositions for treating hematological disorders
US11065231B2 (en)	2017-11-17	2021-07-20	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2019111218A1 (en)	2017-12-08	2019-06-13	Cadila Healthcare Limited	Novel heterocyclic compounds as irak4 inhibitors
CN112105385A (zh)	2017-12-26	2020-12-18	凯麦拉医疗公司	Irak降解剂和其用途
EP3737666A4 (en)	2018-01-12	2022-01-05	Kymera Therapeutics, Inc.	PROTEIN DEGRADANTS AND USES THEREOF
EP3737675A4 (en)	2018-01-12	2022-01-05	Kymera Therapeutics, Inc.	CRBN LIGANDS AND THEIR USES
EP3305786A3 (de)	2018-01-22	2018-07-25	Bayer CropScience Aktiengesellschaft	Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
CA3090275A1 (en)	2018-02-14	2019-08-22	Dana-Farber Cancer Institute, Inc.	Irak degraders and uses thereof
WO2020010177A1 (en)	2018-07-06	2020-01-09	Kymera Therapeutics, Inc.	Tricyclic crbn ligands and uses thereof
TWI721483B (zh)	2018-07-13	2021-03-11	美商基利科學股份有限公司	吡咯并[1,2-b]嗒𠯤衍生物
CA3224949A1 (en)	2018-07-31	2020-02-06	Loxo Oncology, Inc.	Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
JP2022516401A (ja)	2018-11-30	2022-02-28	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
US20220089592A1 (en) *	2019-01-18	2022-03-24	Biogen Ma Inc.	Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
WO2021004533A1 (zh) *	2019-07-10	2021-01-14	南京明德新药研发有限公司	作为irak4和btk多靶点抑制剂的噁唑类化合物
KR20220041124A (ko) *	2019-07-23	2022-03-31	브리스톨-마이어스 스큅 컴퍼니	Irak4 억제제로서 유용한 티에노피리디닐 및 티아졸로피리디닐 화합물
KR20220075232A (ko)	2019-10-02	2022-06-07	(주)카이노스메드	N-(1h-이미다졸-2-일)벤즈아미드 화합물 및 활성 성분으로 이를 포함하는 약학 조성물
EP4076520A4 (en)	2019-12-17	2024-03-27	Kymera Therapeutics Inc	IRAQ DEGRADERS AND USES THEREOF
WO2021127283A2 (en)	2019-12-17	2021-06-24	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
CN115715194A (zh)	2020-04-04	2023-02-24	辉瑞公司	治疗冠状病毒疾病2019的方法
US20230151025A1 (en)	2020-04-07	2023-05-18	Bayer Aktiengesellschaft	Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
EP4142717A4 (en) *	2020-04-28	2024-05-29	Kymera Therapeutics Inc	IRAQ INHIBITORS AND USES THEREOF
TW202210483A (zh)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Irak降解劑之結晶型
IL300310A (en) *	2020-08-03	2023-04-01	Curis Inc	Preparations and methods for treating diseases and disorders
JP2023550591A (ja)	2020-11-02	2023-12-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体
JP2024500247A (ja) *	2020-12-25	2024-01-05	メッドシャインディスカバリーインコーポレイテッド	アミドオキサゾール系化合物
TW202328150A (zh)	2021-09-07	2023-07-16	德商拜耳廠股份有限公司	經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
TW202328151A (zh)	2021-09-07	2023-07-16	德商拜耳廠股份有限公司	經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
CN117177965B (zh) *	2021-12-23	2024-04-30	杭州多域生物技术有限公司	一种五元并六元化合物、制备方法、药物组合物和应用
TW202330546A (zh) *	2021-12-31	2023-08-01	香港商愛科諾生物醫藥(香港)有限公司	具有irak4抑制活性的化合物，包含其的藥物組合物，及其應用
WO2024081893A1 (en) *	2022-10-13	2024-04-18	Kymera Therapeutics, Inc.	Salt forms of irak4 degraders
WO2024092011A1 (en) *	2022-10-25	2024-05-02	Kymera Therapeutics, Inc.	Irak degraders and uses thereof

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100188801B1 (ko)	1990-05-18	1999-06-01	엥겔하르트 라피체	이속사졸-4카복스아미드 및 하이드록시알킬리덴 시아노아세트아미드 및 이들 화합물을 함유하는 약제학적 조성물
DE10023486C1 (de)	2000-05-09	2002-03-14	Schering Ag	Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US6878714B2 (en)	2001-01-12	2005-04-12	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US20030134836A1 (en)	2001-01-12	2003-07-17	Amgen Inc.	Substituted arylamine derivatives and methods of use
WO2004063151A2 (en) *	2003-01-03	2004-07-29	Bristol-Myers Squibb Company	Novel tyrosine kinase inhibitors
US7651469B2 (en)	2003-04-25	2010-01-26	Cook Incorporated	Low friction coated marked wire guide for over the wire insertion of a catheter
EP1620108B1 (en)	2003-05-01	2012-06-06	Bristol-Myers Squibb Company	Pyrazole-amine compounds useful as kinase inhibitors
WO2004103954A1 (ja)	2003-05-20	2004-12-02	Ajinomoto Co., Inc.	アミド誘導体
EP1628661A2 (en)	2003-06-05	2006-03-01	Vertex Pharmaceuticals Incorporated	Modulators of vr1 receptor
EP1493795A1 (de)	2003-07-04	2005-01-05	Collano AG	Klebstoffzusammensetzung
MXPA06003949A (es)	2003-10-07	2006-06-27	Renovis Inc	Compuestos amida como ligandos del canal de ion y su uso.
MY145634A (en) *	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
CA2563941C (en)	2004-04-22	2014-10-07	Bayer Cropscience Lp	Method and composition for controlling weeds with a combination of a preemergent, a post emergent and a three-way broadleaf herbicidal compositions
EP1655297A1 (en)	2004-11-03	2006-05-10	Schering Aktiengesellschaft	Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
US7906533B2 (en)	2004-11-03	2011-03-15	Bayer Schering Pharma Ag	Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1819341A4 (en)	2004-11-10	2011-06-29	Synta Pharmaceuticals Corp	IL-12 MODULATORY CONNECTIONS
MX2007007226A (es)	2004-12-17	2007-08-21	Lilly Co Eli	Antagonistas receptores novedosos de hormona concentradora de melanina (mch).
ES2333243T3 (es)	2004-12-17	2010-02-18	Eli Lilly And Company	Derivados de tiazolopiridinona como antagonistas del receptor de mch.
EP1674467A1 (en)	2004-12-22	2006-06-28	4Sc Ag	2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
WO2007058626A1 (en)	2005-11-16	2007-05-24	S*Bio Pte Ltd	Indazole compounds
EP2295432A1 (en)	2006-02-10	2011-03-16	TransTech Pharma Inc.	Process for the preparation of aminobenzimidazole derivatives
GB0606429D0 (en)	2006-03-30	2006-05-10	Novartis Ag	Organic compounds
WO2007117465A2 (en)	2006-03-31	2007-10-18	Abbott Laboratories	Indazole compounds
US20080293785A1 (en)	2006-04-11	2008-11-27	Connolly Peter J	Substituted benzothiazole kinase inhibitors
RU2459821C2 (ru) *	2006-09-07	2012-08-27	Байоджен Айдек Ма Инк.	Модуляторы киназы, ассоциированной с рецептором интерлейкина-1
AU2007292924A1 (en)	2006-09-07	2008-03-13	Biogen Idec Ma Inc.	IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
US20080153810A1 (en)	2006-11-15	2008-06-26	Forest Laboratories Holdings Limited	Indazole derivatives useful as melanin concentrating receptor ligands
JP5399262B2 (ja)	2006-12-08	2014-01-29	エグゼリクシスパテントカンパニーエルエルシー	Ｌｘｒおよびｆｘｒのモジュレーター
JP4785881B2 (ja)	2007-02-27	2011-10-05	大塚製薬株式会社	医薬
CA2690557A1 (en)	2007-06-14	2008-12-24	Schering Corporation	Imidazopyrazines as protein kinase inhibitors
WO2009011850A2 (en)	2007-07-16	2009-01-22	Abbott Laboratories	Novel therapeutic compounds
ES2457418T3 (es)	2007-07-16	2014-04-25	Abbvie Inc.	Indazoles, bencisoxazoles y bencisotiazoles como inhibidores de proteína cinasas
EP2183224B1 (en)	2007-08-08	2013-11-06	Merck Serono S.A.	6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis
JP5496915B2 (ja)	2008-02-13	2014-05-21	シージーアイファーマシューティカルズ，インコーポレーテッド	６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法
US20110178070A1 (en)	2008-06-24	2011-07-21	Takeda Pharmaceutical Company Limited	PI3K/mTOR INHIBITORS
US8716312B2 (en)	2008-11-19	2014-05-06	Merck Sharp & Dohme Corporation	Inhibitors of diacylglycerol acyltransferase
US8283360B2 (en) *	2008-12-19	2012-10-09	Merck Sharp & Dohme Corp.	Bicyclic heterocyclic derivatives and methods of use thereof
JP2012513435A (ja)	2008-12-23	2012-06-14	エフ．ホフマン−ラロシュアーゲー	Ｐ２ｘ７調節薬としてのジヒドロピリドンアミド
JP6073677B2 (ja)	2009-06-12	2017-02-01	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	縮合複素環式化合物およびそれらの使用
CA2770454A1 (en)	2009-08-19	2011-02-24	Ambit Biosciences Corporation	Biaryl compounds and methods of use thereof
JP2012254939A (ja)	2009-10-07	2012-12-27	Astellas Pharma Inc	オキサゾール化合物
PL2488486T3 (pl)	2009-10-13	2020-01-31	Ligand Pharmaceuticals Inc.	Małocząsteczkowe związki mimetyczne hematopoetycznego czynnika wzrostu i ich zastosowania
EP2560962B1 (en)	2010-04-22	2015-05-20	Janssen Pharmaceutica NV	Indazole compounds useful as ketohexokinase inhibitors
AU2011245299A1 (en)	2010-04-30	2012-08-30	Merck Sharp & Dohme Corp.	Inhibitors of phosphoinositide dependent kinase 1 (PDK1)
SI2585064T1 (sl)	2010-06-24	2017-08-31	Chemocentryx, Inc.	Antagonisti C5AR
RU2604062C2 (ru)	2010-07-13	2016-12-10	Ф.Хоффманн-Ля Рош Аг	ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4
EP3357915A1 (en)	2010-11-19	2018-08-08	Ligand Pharmaceuticals Inc.	Heterocycle amines with anti-inflammatory activity
CA2822166C (en)	2010-12-20	2019-10-29	Merck Serono S.A.	Indazolyl triazole derivatives as irak inhibitors
WO2012142125A2 (en)	2011-04-12	2012-10-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
WO2013042137A1 (en)	2011-09-19	2013-03-28	Aurigene Discovery Technologies Limited	Bicyclic heterocycles as irak4 inhibitors
MX368081B (es)	2011-10-14	2019-09-19	Ambit Biosciences Corp	Compuestos heterociclicos y uso de los mismos como moduladores del receptor de tirosina cinasas tipo iii.
JP6073343B2 (ja)	2011-10-20	2017-02-01	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅＬＬＣ	サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
EP2773207B1 (en) *	2011-10-31	2018-03-07	Merck Sharp & Dohme Corp.	Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
GB201119401D0 (en)	2011-11-10	2011-12-21	Ucb Pharma Sa	Therapeutic agents
KR101385603B1 (ko)	2012-05-17	2014-04-21	한국원자력의학원	벤조티아졸 유도체 및 암 치료를 위한 그의 용도
WO2014003483A1 (en)	2012-06-29	2014-01-03	Hanmi Pharm. Co., Ltd.	Fused pyrimidine derivatives having inhibitory activity on fms kinases
US9085586B2 (en)	2012-07-11	2015-07-21	Nimbus Iris, Inc.	IRAK inhibitors and uses thereof
US9334249B2 (en)	2012-11-03	2016-05-10	Boehringer Ingelheim International Gmbh	Inhibitors of cytomegalovirus
EP2999470B1 (en)	2013-05-22	2017-08-16	Children's Hospital Medical Center	Combination therapy for mds
TWI652014B (zh)	2013-09-13	2019-03-01	美商艾佛艾姆希公司	雜環取代之雙環唑殺蟲劑
TWI667233B (zh)	2013-12-19	2019-08-01	德商拜耳製藥公司	新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
EA201691401A1 (ru)	2014-01-10	2016-11-30	Ориджин Дискавери Текнолоджиз Лимитед	Индазольные соединения в качестве ингибиторов irak4
LT3805233T (lt) *	2014-01-13	2024-05-10	Aurigene Oncology Limited	N-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2- metilpiridin-4-il)oksazol-karboksamido (r) ir (s) enantiomerai, kaip irak4 inhibitoriai, skirti vėžio gydymui
AU2015214366B2 (en)	2014-02-06	2019-04-18	Abbvie, Inc.	6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
BR112016029853A2 (pt)	2014-06-20	2017-08-22	Aurigene Discovery Tech Ltd	compostos de indazol substituído como inibidores de irak4
JO3705B1 (ar)	2014-11-26	2021-01-31	Bayer Pharma AG	إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
CA2984259C (en)	2015-04-30	2024-02-13	Bayer Pharma Aktiengesellschaft	Combinations of inhibitors of irak4 with inhibitors of btk
BR112018000624A2 (pt)	2015-07-15	2018-09-18	Aurigene Discovery Technologies Limited	compostos de indazol e azaindazol como inibidores de irak-4
WO2017009806A1 (en)	2015-07-15	2017-01-19	Aurigene Discovery Technologies Limited	Substituted aza compounds as irak-4 inhibitors
CA2993661A1 (en)	2015-08-04	2017-02-09	Rigel Pharmaceuticals, Inc.	Benzazole compounds and methods for making and using the compounds
US20210292843A1 (en)	2016-10-28	2021-09-23	Children's Hospital Medical Center	Treatment of diseases associated with activated irak
EP3600270B1 (en)	2017-03-31	2023-06-14	Aurigene Oncology Limited	Compounds and compositions for treating hematological disorders
WO2019089580A1 (en)	2017-10-31	2019-05-09	Curis, Inc.	Compounds and compositions for treating hematological disorders
JP2022516401A (ja)	2018-11-30	2022-02-28	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
IL300310A (en)	2020-08-03	2023-04-01	Curis Inc	Preparations and methods for treating diseases and disorders
AU2021381324A1 (en)	2020-11-18	2023-06-15	Curis, Inc.	Methods of treating diseases and disorders
EP4319750A1 (en)	2021-04-08	2024-02-14	Curis, Inc.	Combination therapies for the treatment of cancer
WO2023220227A1 (en)	2022-05-11	2023-11-16	Curis, Inc.	Treating diseases and disorders with irak4-modifying compounds

2015
- 2015-01-12 LT LTEP20211096.1T patent/LT3805233T/lt unknown
- 2015-01-12 NZ NZ760657A patent/NZ760657A/en unknown
- 2015-01-12 EP EP18190333.7A patent/EP3466955B1/en active Active
- 2015-01-12 SG SG10201811204RA patent/SG10201811204RA/en unknown
- 2015-01-12 IL IL302878A patent/IL302878B1/en unknown
- 2015-01-12 WO PCT/IB2015/050217 patent/WO2015104688A1/en active Application Filing
- 2015-01-12 FI FIEP20211096.1T patent/FI3805233T3/fi active
- 2015-01-12 EA EA201891917A patent/EA038748B1/ru unknown
- 2015-01-12 DK DK18190333.7T patent/DK3466955T3/da active
- 2015-01-12 MY MYPI2021007377A patent/MY197116A/en unknown
- 2015-01-12 LT LTEP18190333.7T patent/LT3466955T/lt unknown
- 2015-01-12 RS RS20210039A patent/RS61448B1/sr unknown
- 2015-01-12 MX MX2016009013A patent/MX359909B/es active IP Right Grant
- 2015-01-12 KR KR1020167021713A patent/KR102392684B1/ko active IP Right Grant
- 2015-01-12 BR BR112016016158-0A patent/BR112016016158B1/pt active IP Right Grant
- 2015-01-12 IL IL311677A patent/IL311677A/en unknown
- 2015-01-12 ES ES18190333T patent/ES2846678T3/es active Active
- 2015-01-12 AU AU2015205374A patent/AU2015205374B2/en active Active
- 2015-01-12 TR TR2018/15683T patent/TR201815683T4/tr unknown
- 2015-01-12 IL IL284952A patent/IL284952B/en unknown
- 2015-01-12 EP EP23214923.7A patent/EP4353324A2/en active Pending
- 2015-01-12 ES ES15735499.4T patent/ES2692852T3/es active Active
- 2015-01-12 RS RS20181355A patent/RS58024B1/sr unknown
- 2015-01-12 HU HUE15735499A patent/HUE041926T2/hu unknown
- 2015-01-12 EA EA201691428A patent/EA031913B1/ru unknown
- 2015-01-12 PT PT202110961T patent/PT3805233T/pt unknown
- 2015-01-12 JP JP2016563278A patent/JP6479850B2/ja active Active
- 2015-01-12 KR KR1020227014075A patent/KR102574390B1/ko active IP Right Grant
- 2015-01-12 EP EP15735499.4A patent/EP3094329B1/en active Active
- 2015-01-12 EP EP20211096.1A patent/EP3805233B1/en active Active
- 2015-01-12 SG SG11201605486WA patent/SG11201605486WA/en unknown
- 2015-01-12 US US15/111,000 patent/US9732095B2/en active Active
- 2015-01-12 NZ NZ722019A patent/NZ722019A/en unknown
- 2015-01-12 CU CU2016000111A patent/CU24389B1/es unknown
- 2015-01-12 PL PL15735499T patent/PL3094329T3/pl unknown
- 2015-01-12 SI SI201530477T patent/SI3094329T1/sl unknown
- 2015-01-12 PL PL18190333T patent/PL3466955T3/pl unknown
- 2015-01-12 SI SI201531483T patent/SI3466955T1/sl unknown
- 2015-01-12 IL IL294895A patent/IL294895B2/en unknown
- 2015-01-12 LT LTEP15735499.4T patent/LT3094329T/lt unknown
- 2015-01-12 DK DK15735499.4T patent/DK3094329T3/en active
- 2015-01-12 CA CA2935887A patent/CA2935887A1/en active Pending
- 2015-01-12 CN CN201580013752.4A patent/CN106456619B/zh active Active
- 2015-01-12 CN CN202010147212.8A patent/CN111362966B/zh active Active
- 2015-01-12 PT PT181903337T patent/PT3466955T/pt unknown
- 2015-01-12 PT PT15735499T patent/PT3094329T/pt unknown
- 2015-01-12 DK DK20211096.1T patent/DK3805233T3/da active
- 2015-01-12 KR KR1020237029626A patent/KR20230129622A/ko not_active Application Discontinuation
- 2015-01-12 HU HUE18190333A patent/HUE052252T2/hu unknown
2016
- 2016-07-03 IL IL246575A patent/IL246575B/en active IP Right Grant
- 2016-07-07 PH PH12016501344A patent/PH12016501344A1/en unknown
2017
- 2017-05-24 HK HK17105239.1A patent/HK1231410A1/zh unknown
- 2017-08-02 US US15/667,173 patent/US10047104B2/en active Active
2018
- 2018-08-03 US US16/054,512 patent/US10640517B2/en active Active
- 2018-10-30 HR HRP20181795TT patent/HRP20181795T1/hr unknown
- 2018-11-20 AU AU2018267569A patent/AU2018267569B2/en active Active
- 2018-12-21 CY CY20181101382T patent/CY1121433T1/el unknown
2019
- 2019-02-06 JP JP2019019229A patent/JP6750053B2/ja active Active
- 2019-12-11 IL IL271364A patent/IL271364B/en unknown
- 2019-12-17 AU AU2019283795A patent/AU2019283795B2/en active Active
2020
- 2020-02-19 US US16/795,394 patent/US10995100B2/en active Active
- 2020-03-13 PH PH12020500529A patent/PH12020500529A1/en unknown
- 2020-06-25 JP JP2020109507A patent/JP6977111B2/ja active Active
- 2020-11-23 ZA ZA2020/07274A patent/ZA202007274B/en unknown
- 2020-11-23 ZA ZA2020/07273A patent/ZA202007273B/en unknown
2021
- 2021-01-19 HR HRP20210094TT patent/HRP20210094T1/hr unknown
- 2021-01-29 CY CY20211100076T patent/CY1123936T1/el unknown
- 2021-04-30 US US17/245,611 patent/US11691987B2/en active Active
- 2021-06-08 AU AU2021203761A patent/AU2021203761B2/en active Active
- 2021-11-10 JP JP2021183016A patent/JP7262553B2/ja active Active
2023
- 2023-04-11 JP JP2023063800A patent/JP2023085526A/ja active Pending
- 2023-04-28 US US18/141,008 patent/US11981685B2/en active Active
- 2023-09-01 AU AU2023222987A patent/AU2023222987A1/en active Pending

Also Published As

Publication number	Publication date
IL294895B2 (en)	2023-10-01
SG11201605486WA (en)	2016-08-30
EP3805233B1 (en)	2024-03-06
EA031913B1 (ru)	2019-03-29
EP3094329A4 (en)	2017-05-31
BR112016016158B1 (pt)	2022-12-13
PT3094329T (pt)	2018-11-26
US20220056046A1 (en)	2022-02-24
AU2018267569B2 (en)	2019-09-26
HRP20210094T1 (hr)	2021-03-05
AU2021203761A1 (en)	2021-07-08
IL271364A (en)	2020-01-30
EA038748B1 (ru)	2021-10-14
IL284952A (en)	2021-08-31
FI3805233T3 (fi)	2024-04-17
JP6977111B2 (ja)	2021-12-08
ZA202007273B (en)	2023-11-29
IL302878A (en)	2023-07-01
TR201815683T4 (tr)	2018-11-21
CN111362966A (zh)	2020-07-03
JP2022024021A (ja)	2022-02-08
US10640517B2 (en)	2020-05-05
IL302878B1 (en)	2024-05-01
US10995100B2 (en)	2021-05-04
WO2015104688A1 (en)	2015-07-16
CA2935887A1 (en)	2015-07-16
IL271364B (en)	2021-08-31
JP6479850B2 (ja)	2019-03-06
US20160340366A1 (en)	2016-11-24
PL3094329T3 (pl)	2019-03-29
NZ760657A (en)	2022-07-01
MX2016009013A (es)	2017-01-23
CY1121433T1 (el)	2020-05-29
RS58024B1 (sr)	2019-02-28
US20200190112A1 (en)	2020-06-18
PH12016501344A1 (en)	2016-08-15
CN106456619A (zh)	2017-02-22
PT3466955T (pt)	2021-01-29
IL311677A (en)	2024-05-01
LT3805233T (lt)	2024-05-10
US11981685B2 (en)	2024-05-14
CN111362966B (zh)	2022-03-11
EP4353324A2 (en)	2024-04-17
AU2019283795B2 (en)	2021-04-01
EP3094329B1 (en)	2018-09-26
MY197116A (en)	2023-05-26
US9732095B2 (en)	2017-08-15
KR20220061266A (ko)	2022-05-12
CU24389B1 (es)	2019-04-04
US20180022758A1 (en)	2018-01-25
AU2015205374B2 (en)	2018-08-23
US10047104B2 (en)	2018-08-14
DK3805233T3 (da)	2024-04-15
HK1231410A1 (zh)	2017-12-22
ZA202007274B (en)	2023-11-29
RS61448B1 (sr)	2021-03-31
JP2019077729A (ja)	2019-05-23
EA201691428A1 (ru)	2016-12-30
HUE052252T2 (hu)	2021-04-28
ES2846678T3 (es)	2021-07-28
KR20160115934A (ko)	2016-10-06
JP6750053B2 (ja)	2020-09-02
AU2021203761B2 (en)	2023-06-01
HRP20181795T1 (hr)	2019-01-25
SG10201811204RA (en)	2019-01-30
AU2018267569A1 (en)	2018-12-06
CN106456619B (zh)	2020-03-27
EP3805233A1 (en)	2021-04-14
IL294895B1 (en)	2023-06-01
DK3094329T3 (en)	2018-11-19
ES2692852T3 (es)	2018-12-05
IL246575B (en)	2019-12-31
PH12020500529A1 (en)	2021-07-26
HUE041926T2 (hu)	2019-06-28
JP2017502088A (ja)	2017-01-19
AU2015205374A1 (en)	2016-07-28
BR112016016158A2 (pt)	2017-08-08
CU20160111A7 (es)	2017-03-03
US20230331740A1 (en)	2023-10-19
EP3466955A1 (en)	2019-04-10
KR20230129622A (ko)	2023-09-08
IL294895A (en)	2022-09-01
JP2023085526A (ja)	2023-06-20
SI3466955T1 (sl)	2021-05-31
DK3466955T3 (da)	2021-02-01
EA201891917A1 (ru)	2019-02-28
IL284952B (en)	2022-08-01
SI3094329T1 (sl)	2019-02-28
NZ722019A (en)	2022-07-01
LT3466955T (lt)	2021-02-25
PL3466955T3 (pl)	2021-06-28
IL246575A0 (en)	2016-08-31
LT3094329T (lt)	2018-11-26
AU2019283795A1 (en)	2020-01-16
KR102392684B1 (ko)	2022-04-29
US11691987B2 (en)	2023-07-04
EP3466955B1 (en)	2020-12-16
CY1123936T1 (el)	2022-05-27
JP2020164546A (ja)	2020-10-08
MX359909B (es)	2018-10-16
US20180370988A1 (en)	2018-12-27
EP3094329A1 (en)	2016-11-23
AU2023222987A1 (en)	2023-09-21
JP7262553B2 (ja)	2023-04-21
KR102574390B1 (ko)	2023-09-04

Publication	Publication Date	Title
PT3805233T (pt)	2024-04-15	Enantiómeros (r) e (s) de n-(5-(3-hidroxipirrolidin-1-il)-2 morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)oxazole-carboxamida como inibidores de irak4 para o tratamento de cancro
HK1247922A1 (zh)	2018-10-05	用於治療癌症的吲哚胺2，3-雙加氧酶抑制劑
IL255509B (en)	2021-04-29	Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
PH12016501972B1 (en)	2016-12-19	Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
IL253945B (en)	2021-05-31	kdm1a inhibitors to treat the disease
EP3347368A4 (en)	2019-01-23	COMPOUNDS AND FORMULATIONS FOR TREATING OPHTHALMIC DISEASES
IL272444A (en)	2020-03-31	Compounds, their salts and methods for treating diseases
MA39986A (fr)	2017-03-01	Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
IL261015B (en)	2021-10-31	History of methylamine as lysyl oxidase inhibitors for cancer treatment
PH12016502291A1 (en)	2017-02-13	Indolizine derivatives as phosphoinositide 3-kinases inhibitors
IL254266B (en)	2020-06-30	Glucosylceramide synthase inhibitors for the treatment of diseases
EP3374502A4 (en)	2019-07-10	METHOD FOR THE TREATMENT OF CORNEAL DYSTROPHIES
HK1252813A1 (zh)	2019-06-06	用於治療社交障礙和藥物使用障礙的治療性化合物和組合物
EP3169405A4 (en)	2018-01-24	Methods, compounds, and compositions for the treatment of musculoskeletal diseases
IL249502A0 (en)	2017-02-28	Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases
SI3452465T1 (sl)	2021-04-30	Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni
EP3148570A4 (en)	2018-02-14	Pharmaceutical composition for preventing or treating skin rash
EP3371154A4 (en)	2019-06-05	HETEROCYCLIC DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS
EP3324993A4 (en)	2019-03-27	COMPOSITION FOR THE TREATMENT OF RSV
EP3354271A4 (en)	2018-12-26	Agent for treating arthrological diseases
AU2015902659A0 (en)	2015-07-16	Therapeutic compounds and compositions for treating social disorders and substance use disorders
AU2015901799A0 (en)	2015-05-28	Composition for the treatment of skin conditions
EP3125903A4 (en)	2017-11-15	Method for use of homopiperazinium compounds in the treatment of cancer